Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 14.65$. Average daily volumn in 3 months 2.6M. Market cap 46.30B

Stock symbol : TAK. Exchange : NYSE. Currency : USD
Lastest price : 14.91$. Total volume : 1.46M. Market state POST
Click reload if you want to check the lastest price on market!!!

Takeda Pharmaceutical Company Limited (TAK)
Last Price

Previous Close14.94
Day Range14.83-14.95
Bid14.91 x 4k
Ask15.04 x 4k
Average Volume2.6M
Market Cap46.3B
52 Week Range13.17-17.43
Trailing P/E26.13
Foward P/E7.13
Dividend (Yield %)5.38%
Ex-Dividend Date2021-09-29

Financial Details

According to Takeda Pharmaceutical Company Limited's financial reports the company's revenue in 2022 were 3.57T an increase(0%) over the years 2021 revenue that were of 3.2T. In 2022 the company's total earnings were 230.06B while total earnings in 2021 were 376B(-38.83%).

Loading ...


Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro... , Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Market Cap:
Total Assets:
Total Cash:

News about "Takeda Pharmaceutical Company Limited"


Takeda Pharmaceutical: A Bright Decade Ahead

Source from : Seeking Alpha - 2 days ago

Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China & emerging markets will be key to growth. See more on TAK stock here.See details»

Takeda Pharmaceutical (NYSE:TAK) Releases FY 2022 Earnings Guidance

Source from : Defense World - 18 hours ago

Takeda Pharmaceutical (NYSE:TAK โ€“ Get Rating) updated its FY 2022 earnings guidance on Wednesday. The company provided earnings per share guidance of $3.99-$3.99 for the period. The company issued ...See details»

Takeda Pharmaceutical Company Limited [TAK] is 4.62% higher this YTD. Is it still time to buy?

Source from : dbtnews - 12 days ago

Silvergate Capital Corporation loss -10.92% or -7.81 points... Takeda Pharmaceutical Company Limited [NYSE: TAK] price surged by 2.37 percent to reach at $0.33. The company report on May 11, 2022 that ...See details»

Takeda Pharmaceutical Co. Ltd. ADR

Source from : Wall Street Journal - 5 days ago

1 Day TAK 0.96% DJIA 0.03% S&P 500 0.01% Health Care/Life Sciences -0.49% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...See details»


Takeda Pharmaceutical Co launches hemophilia drug Adynovate

Source from : - 9 days ago

Adynovate is an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology for hemophilia A patients. It offers effective bleed resolution with ...See details»

Short Interest in Takeda Pharmaceutical Company Limited (NYSE:TAK) Decreases By 19.8%

Source from : ETF Daily News - 1 month ago

Takeda Pharmaceutical Company Limited (NYSE:TAK โ€“ Get Rating) was the recipient of a significant drop in short interest in the month of March. As of March 31st, there was short interest ...See details»

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q4 2022 Results - Earnings Call Transcript

Source from : Seeking Alpha - 13 days ago

Q4 2022 Earnings Conference Call May 11, 2022 06:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - CEO Andy Plump ...See details»

Takeda Pharmaceutical Company Limited (TKPHF)

Source from : Yahoo Finance - 1 month ago

April 26, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top ... Co Ltd (NYSE: TAK) shared new ...See details»

Takeda Pharmaceutical Co Ltd ADR - Stock Quote TAK

Source from : Morningstar%2c Inc. - 6 days ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»

Takeda Pharma FY21 Core Profit Rises

Source from : Business Insider - 14 days ago

(RTTNews) - Takeda Pharmaceutical Company Limited (TKPHF.PK, TAK) reported fiscal 2021 core net profit of 663.7 million yen, an increase of 1.3% from prior year. Core earnings per share was 425 ...See details»


Japanโ€™s Takeda Pharma says full-year profit slid 9.5%

Source from : KFGO - 15 days ago

Takeda Pharmaceutical Co said on Wednesday that 12-month operating profit slid 9.5% from the previous year. Operating profit for Japan's largest drugmaker in the year that ended on March 31 came in at ...See details»

Takeda Pharmaceutical Company Limited (4502.T)

Source from : Yahoo Finance - 1 month ago

April 26, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0โ„ข ...See details»


Takeda Pharma unveils haemophilia drug Adynovate in India

Source from : Daily - 9 days ago

The prophylaxis treatment is named Adynovate and is an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for haemophilia A ...See details»

Dengue Vaccines Market Size, Share and Forecast | Sanofi, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, Merck & Co

Source from : Digital Journal - 28 days ago

Sanofi, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, and Merck & Co. The research gives an excellent insight of the important macroeconomic aspects influencing the growth of the Dengue ...See details»